Similarly, in CheckMate-067 (nivolumab + ipilimumab vs. single agent nivolumab vs. single agent ipilimumab) data on specific OS and PFS for BRAF V600K melanoma are not reported, although results seemed promising for BRAF mutated melanoma with better OS and PFS (5-Y-OS 60% vs. 48% and 5-Y-PFS 38% vs. 35%) compared to WT melanoma, especially in the nivolumab + ipilimumab arm [31]. Here, BRAF is linked to melanoma.